MedTrace Logo

Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

NCT00136760 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2015-10-07

Study results available
· View outcomes & findings →

Summary

There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers. The aims of this study are to investigate the separate and combined effects of bupropion and a voucher incentive program on smoking in people with schizophrenia.

Conditions

  • Schizophrenia and Disorders With Psychotic Features
  • Tobacco Use Disorder

Interventions

DRUG

Bupropion

Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)

DRUG

Contingent reinforcement plus placebo

contingent reinforcement plus placebo (3 weeks)

DRUG

non-contingent reinforcement plus bupropion

non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)

DRUG

Non-contingent reinforcement plus placebo

Non-contingent reinforcement plus placebo

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Brown University

    lead OTHER

Principal Investigators

  • Jennifer W. Tidey · Brown University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00136760 on ClinicalTrials.gov